The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

@article{Zinman2007TheEO,
  title={The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.},
  author={Bernard Zinman and Byron J Hoogwerf and Santiago Dur{\'a}n Garc{\'i}a and Den{\'a}i R. Milton and Joseph M. Giaconia and Dennis D. Kim and Michael E. Trautmann and Robert G Brodows},
  journal={Annals of internal medicine},
  year={2007},
  volume={146 7},
  pages={477-85}
}
Context The effects of adding exenatide to thiazolidinediones (TZDs) for treating type 2 diabetes are not clear. Contribution The investigators of this double-blind trial randomly assigned 233 adults with type 2 diabetes that was suboptimallycontrolled with TZD (with or without metformin) to twice-daily injections of exenatide or placebo. At 16 weeks, exenatide reduced hemoglobin A1c levels (mean difference, 0.98%), fasting glucose levels (mean difference, 1.69 mmol/L [30.5 mg/dL]), and body… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

Diabetes, metabolic syndrome and obesity : targets and therapy • 2010
View 2 Excerpts
Highly Influenced

Incretin hormones and the satiation signal

International Journal of Obesity • 2013

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…